319 related articles for article (PubMed ID: 18585835)
41. Combination therapy with mycophenolate mofetil and prednisone in steroid-resistant idiopathic membranoproliferative glomerulonephritis.
Yuan M; Zou J; Zhang X; Liu H; Teng J; Zhong Y; Ding X
Clin Nephrol; 2010 May; 73(5):354-9. PubMed ID: 20420795
[TBL] [Abstract][Full Text] [Related]
42. Mycophenolate mofetil therapy in children with idiopathic membranous nephropathy.
Bhimma R; Naicker E; Ramdial PK
Clin Nephrol; 2013 Dec; 80(6):441-8. PubMed ID: 24262490
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of traditional chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial.
Chen Y; Deng Y; Ni Z; Chen N; Chen X; Shi W; Zhan Y; Yuan F; Deng W; Zhong Y
Am J Kidney Dis; 2013 Dec; 62(6):1068-76. PubMed ID: 23810688
[TBL] [Abstract][Full Text] [Related]
44. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group.
Transplantation; 1996 Mar; 61(5):722-9. PubMed ID: 8607174
[TBL] [Abstract][Full Text] [Related]
45. Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients--assessment of renal and allograft function, cardiovascular risk factors and immune monitoring.
Cicinnati VR; Yu Z; Klein CG; Sotiropoulos GC; Saner F; Malagó M; Frilling A; Gerken G; Broelsch CE; Beckebaum S
Aliment Pharmacol Ther; 2007 Nov; 26(9):1195-208. PubMed ID: 17944734
[TBL] [Abstract][Full Text] [Related]
46. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial.
Frisch G; Lin J; Rosenstock J; Markowitz G; D'Agati V; Radhakrishnan J; Preddie D; Crew J; Valeri A; Appel G
Nephrol Dial Transplant; 2005 Oct; 20(10):2139-45. PubMed ID: 16030050
[TBL] [Abstract][Full Text] [Related]
47. High-dose mycophenolate mofetil in the treatment of posttransplant glomerular disease in the allograft: a case series.
Wu J; Jaar BG; Briggs WA; Choi MJ; Kraus ES; Racusen LC; Atta MG; Samaniego MD
Nephron Clin Pract; 2004; 98(3):c61-6. PubMed ID: 15528938
[TBL] [Abstract][Full Text] [Related]
48. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
[TBL] [Abstract][Full Text] [Related]
49. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide.
Wang J; Hu W; Xie H; Zhang H; Chen H; Zeng C; Liu Z; Li L
Lupus; 2007; 16(9):707-12. PubMed ID: 17728363
[TBL] [Abstract][Full Text] [Related]
50. Successful mycophenolate mofetil treatment of glomerular disease.
Briggs WA; Choi MJ; Scheel PJ
Am J Kidney Dis; 1998 Feb; 31(2):213-7. PubMed ID: 9469489
[TBL] [Abstract][Full Text] [Related]
51. The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis.
Ren P; Han F; Chen L; Xu Y; Wang Y; Chen J
Am J Nephrol; 2012; 36(3):271-7. PubMed ID: 22965140
[TBL] [Abstract][Full Text] [Related]
52. Mycophenolate mofetil in high-risk patients with primary glomerulonephritis: results of a 1-year prospective study.
Dimkovic N; Jovanovic D; Kovacevic Z; Rabrenovic V; Nesic V; Savin M; Mitic B; Ratkovic M; Curic S; Mitic I; Pljesa S; Perunicic-Pekovic G; Marinkovic J; Popovic J; Vujic D
Nephron Clin Pract; 2009; 111(3):c189-96. PubMed ID: 19194109
[TBL] [Abstract][Full Text] [Related]
53. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
[TBL] [Abstract][Full Text] [Related]
54. Lupus nephritis: treatment with mycophenolate mofetil.
Kapitsinou PP; Boletis JN; Skopouli FN; Boki KA; Moutsopoulos HM
Rheumatology (Oxford); 2004 Mar; 43(3):377-80. PubMed ID: 14963204
[TBL] [Abstract][Full Text] [Related]
55. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement.
Hu W; Liu C; Xie H; Chen H; Liu Z; Li L
Nephrol Dial Transplant; 2008 Apr; 23(4):1307-12. PubMed ID: 18065810
[TBL] [Abstract][Full Text] [Related]
56. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.
Hu W; Liu Z; Chen H; Tang Z; Wang Q; Shen K; Li L
Chin Med J (Engl); 2002 May; 115(5):705-9. PubMed ID: 12133539
[TBL] [Abstract][Full Text] [Related]
57. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study.
Maes BD; Oyen R; Claes K; Evenepoel P; Kuypers D; Vanwalleghem J; Van Damme B; Vanrenterghem YF
Kidney Int; 2004 May; 65(5):1842-9. PubMed ID: 15086925
[TBL] [Abstract][Full Text] [Related]
58. Mycophenolate mofetil plus prednisone for inducing remission of Henoch-Schönlein purpura nephritis: a retrospective study.
Han F; Chen LL; Ren PP; Le JY; Choong PJ; Wang HJ; Xu Y; Chen JH
J Zhejiang Univ Sci B; 2015 Sep; 16(9):772-9. PubMed ID: 26365119
[TBL] [Abstract][Full Text] [Related]
59. Outcome of idiopathic membranous nephropathy using targeted stepwise immunosuppressive treatment strategy.
Aaltonen S; Honkanen E
Nephrol Dial Transplant; 2011 Sep; 26(9):2871-7. PubMed ID: 21427071
[TBL] [Abstract][Full Text] [Related]
60. Membranous nephropathy with crescents: a series of 19 cases.
Rodriguez EF; Nasr SH; Larsen CP; Sethi S; Fidler ME; Cornell LD
Am J Kidney Dis; 2014 Jul; 64(1):66-73. PubMed ID: 24709471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
